|
Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus Clinical research trials and Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus. Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus clinical trial. Human subjects often receive the most effective healthcare possible for their Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus  Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus
Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus
For Condition: Gastric Cancer,Esophageal Neoplasms
Status: Suspended
Sponsor(s): Tularik ,
Synopsis: This is a clinical research study of T900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on a weekly basis with an intravenous injection of the study drug.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Histologically or cytologically confirmed diagnosis of gastric cancer or adenocarcinoma of the esophagus - Subjects must have received 1-2 regimens of prior chemotherapy - At least 18 years of age - Bidimensionally measurable disease amenable to CT scanning. At least one lesion must be least 1 X 1 cm in size. - Karnofsky performance status of at least 70% - Estimated life expectancy of at least 12 weeks - Females of childbearing potential must have a negative pregnancy test and agree to use an effective contraceptive - Subject must be able to comply with study procedures and follow-up examinations. - Signed written informed consent - Lab Values (obtained 7 days prior to study enrollment): * ANC at least 1.5x10e9/L, * Platelet count at least 100x10e9/L, * Creatinine within 2 times upper limit of normal * AST and ALT within 5 times upper limit of normal * Bilirubin within 1.5 times upper limit of normal * Albumin great than 2.5 g/dL Exclusion Criteria - Severe, concurrent disease, infection or co-morbidity that, in the judgment of the investigator, would make the subject inappropriate for enrollment - NYHA Class III/IV cardiac disease, left ventricular ejection fraction (LVEF) of <50%, or acute anginal symptoms - Patients who have received any investigational agent within 4 weeks of enrollment - Patients who are pregnant or breast-feeding - History of prior malignancy other than gastric cancer or adenocarcinoma of the esophagus within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix - History of central nervous system metastases or carcinomatous meningitis - Major surgery within 4 weeks of enrollment
Total Enrollment: 70
Location and Contact Information:
Overall Study Official:
KerrieBoyd, Study Chair,
Pacific Oncology Associates
Los Gatos, California, 95032
United States
Moffitt Cancer Center
Tampa, Florida, 33612
United States
Scripps Health Center
San Diego, California, 92137
United States
Ireland Cancer Center
Cleveland, Ohio, 44106
United States
University of New Mexico Cancer Research and Treatment Center
Albuquerque, New Mexico, 87131
United States
Additional Information:
Study ID Numbers: T-607-006;
Study Start Date: September 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048529
Other Gastric Cancer Studies:
1. Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer
2. Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
3. Irinotecan and Capecitabine in Treating Patients With Solid Tumors
4. Phase I Study of SU006668 in Patients With Advanced Solid Tumors
5. Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer
Related Studies:
Other Gastric Cancer Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
Study of T900607-sodium in subjects with previously treated gastric cancer or adenocarcinoma of the esophagus
|
|
|
|
|
|
|
|
